Obsessive-Compulsive Disorder study: 3 vs Methamphetamine
Official title MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)
ClinicalTrials.gov ID: NCT05783817
What this study is testing
What is MDMA?
This is an investigational drug being studied as a potential treatment for Obsessive-Compulsive Disorder (OCD). It is designed to act as a psychoactive substance that affects brain chemicals, though its specific mechanism for treating OCD is still being researched.
Also referred to as 3,4-Methyl enedioxy methamphetamine.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study wants to see if this treatment is safe and if it might help reduce symptoms of obsessive-compulsive disorder.
- Who it's for
- The study is looking for adults who have been diagnosed with obsessive-compulsive disorder.
- What's involved
- Participants will receive a dose of MDMA (a medication) and attend sessions of cognitive behavioral therapy (a type of talk therapy).
- Time commitment
- The source text does not specify the total duration or the number of visits required.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- At least 18 years old
- Fluent in speaking and reading the predominantly used or recognized language of the study site
- Able to swallow pills
- Meet the criteria for OCD diagnosis
- YBOCS total score of at least 16
You likely can't join if
- Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
- Weigh less than 48 kilograms (kgs)
- Any current problem which, in the opinion of the investigator or study physician, might interfere with participation
See the full eligibility criteria
- At least 18 years old
- Fluent in speaking and reading the predominantly used or recognized language of the study site
- Able to swallow pills
- Meet the criteria for OCD diagnosis
- YBOCS total score of at least 16
- Not on psychotropic medications 1 month prior to study enrollment
- Able to tolerate a treatment-free period
- Able to tolerate study procedures
- Failed at least 1 prior trial of standard first-line OCD treatment
- Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to the Experimental Session, not enroll in any other treatment clinical trials during...
- Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
- Weigh less than 48 kilograms (kgs)
- Any current problem which, in the opinion of the investigator or study physician, might interfere with participation
The study team makes the final eligibility decision.
Where it is enrolling
- Palo Alto, California, United States
Compensation & support
A stipend or payment for your time may be offered.
No amount is published here because ClinicalTrials.gov has no reliable field for payment or travel support. Ask the study team what's actually covered (payment for your time, travel, parking, or other study costs), and never join a trial for the compensation alone.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team, so confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Palo Alto, California, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.